Eastern Cooperative Oncology Group (Main Institution)

东部肿瘤合作组(主要机构)

基本信息

项目摘要

DESCRIPTION (provided by applicant): The University of Pittsburgh Cancer Institute (UPCI) was formed in 1985, and over the twenty-three years since then has amassed a cadre of more than 400 basic and clinical investigators with broad basic and clinical expertise that relates to the ECOG in relation to many of its disease and modality committees. The Eastern Cooperative Oncology Group (ECOG) is the major extramural focus of multi-modal clinical investigations in adult solid tumors of the UPCI. UPCI is based in the hospitals of the University of Pittsburgh Medical Center (UPMC), a health system consisting of UPMC Presbyterian (PUH), UPMC Montefiore (MUH), the Eye and Ear Hospital and Institute, UPMC Shadyside Hospital, Western Psychiatric Hospital and Clinic, Falk Clinic, and the Magee Women's Hospital. In 2002, The UPMC Cancer Centers were formed, including a broad array of more than 45 locations that serve as the base of operations for full-time and clinical faculty of the UPCI who are active in ECOG within Pittsburgh and across the region. These include UPMC Shadyside, UPMC Bedford Memorial, UPMC Braddock, UPMC Horizon-Greenville and Shenango Valley, UPMC Lee Regional, UPMC McKeesport, UPMC Northwest Franklin and Oil City, UPMC Passavant, Cranberry, UPMC Southside, Children's Hospital of Pittsburgh, UPMC St. Margaret's, UPMC Mercy, Magee Women's Hospital, Beaver Valley, Latrobe Area Hospital, Heritage Valley Health System, Westmorland Hospital, Jameson Health System, Jefferson Regional Medical Center, Memorial Medical Center, The Washington Hospital, Uniontown Hospital and Frick Hospital as well as the UPMC Rehabilitation Hospital. These facilities provide for a cachement area that extends across Western Pennsylvania from W. Virginia to Ohio and New York State. The Oakland Veterans Administration Medical Center is a consortium member of ECOG, affording access to ECOG studies for patients of the VA system. UPMC relocated inpatient UPCI clinical facilities to MUH in 1993, and to the Hillman Cancer Center - UPMC Shadyside Medical Center in 2003, with full service inpatient Medical Oncology, Surgical Oncology, and Hematology/BMT as well as a satellite Clinical Translational Science Institute (CTSI) in the outpatient Hillman Cancer Center Ambulatory Care Facility. A range of ECOG studies with laboratory components are being conducted on this CTSI, providing support for protocol therapy of patients on ECOG trials beyond what would be possible with third party payer coverage. The basic cancer research space of UPCI has been consolidated in the Hillman Cancer Center Research Pavilion that was completed in 2002, offering state-of-the-art research laboratories contiguous with the outpatient and inpatient facilities. Those that relate directly to ECOG include the Clinical Immunologic Monitoring Laboratory (IMCPL) which serves as the Core Immunological Monitoring Laboratory for ECOG, the Serum and Tissue Bank, and Flow Cytometry FACS/Hybridoma facilities. Separately located on the campus of the UPMC are Crystallography, Peptide Synthesis, and Oligonucleotide Synthesis facilities. The Clinical Research Services are now located in the Hillman Cancer Center Cooper Ambulatory Pavilion, while the Biostatistical Office is located at the Sterling Building several blocks closer to the Oakland Campus. UPCI and UPMC have developed as matrix organizations in which the traditional academic departments and divisions of Hematology/Oncology, Surgical Oncology, and Radiation Oncology are configured along disease-oriented lines to facilitate the growth and development of interdisciplinary disease-oriented and modality programs. RELEVANCE: The Eastern Cooperative Oncology Group (ECOG) is the major extramural focus of multi-modal clinical Investigations In adult solid tumors of the UPCI. UPCI is based in the hospitals of the University of Pittsburgh Medical Center (UPMC).
描述(由申请人提供):匹兹堡大学癌症研究所(UPCI)成立于1985年,从那时起的23年中,已经积累了400多名基础和临床研究人员,他们具有广泛的基础和临床专业知识,与ECOG及其许多疾病和模式委员会有关。东部肿瘤合作小组(ECOG)是UPCI成人实体瘤多模式临床研究的主要校外重点。UPCI以匹兹堡大学医学中心(UPMC)的医院为基础,UPMC医学中心是一个由UPMC长老会医院(PUH), UPMC Montefiore (MUH),眼耳医院和研究所,UPMC Shadyside医院,西方精神病院和诊所,福克诊所和Magee妇女医院组成的卫生系统。2002年,UPMC癌症中心成立,包括超过45个地点,作为UPCI的全职和临床教师的操作基地,他们活跃在匹兹堡和整个地区的ECOG。这些包括UPMC Shadyside, UPMC Bedford Memorial, UPMC Braddock, UPMC horizo - greenville和Shenango Valley, UPMC Lee地区,UPMC McKeesport, UPMC西北富兰克林和石油城,UPMC Passavant, Cranberry, UPMC Southside,匹兹堡儿童医院,UPMC St. Margaret's, UPMC Mercy, Magee妇女医院,Beaver Valley, Latrobe地区医院,遗产谷卫生系统,Westmorland医院,Jameson卫生系统,杰斐逊地区医疗中心,Memorial Medical Center,华盛顿医院,联合镇医院,弗里克医院以及UPMC康复医院。这些设施提供了一个从西弗吉尼亚州到俄亥俄州和纽约州的横跨宾夕法尼亚州西部的缓冲区域。奥克兰退伍军人管理医疗中心是ECOG的联盟成员,为VA系统的患者提供ECOG研究。UPMC于1993年将UPCI住院临床设施搬迁到MUH,并于2003年将UPMC Shadyside医疗中心搬迁到Hillman癌症中心- UPMC Shadyside医疗中心,提供全面服务的住院内科肿瘤学,外科肿瘤学和血液学/BMT,以及门诊Hillman癌症中心门诊护理设施的卫星临床转化科学研究所(CTSI)。该CTSI正在进行一系列具有实验室成分的ECOG研究,为ECOG试验患者的方案治疗提供支持,这超出了第三方付款人覆盖范围。UPCI的基础癌症研究空间已经在2002年完成的希尔曼癌症中心研究馆中得到了巩固,提供了与门诊和住院设施相邻的最先进的研究实验室。与ECOG直接相关的包括临床免疫监测实验室(IMCPL),作为ECOG的核心免疫监测实验室,血清和组织库,以及流式细胞仪FACS/杂交瘤设施。位于UPMC校园内的分别是晶体学,肽合成和寡核苷酸合成设施。临床研究服务现在位于希尔曼癌症中心库珀门诊馆,而生物统计办公室位于离奥克兰校区近几个街区的斯特林大楼。UPCI和UPMC已经发展成为矩阵组织,其中传统的血液学/肿瘤学,外科肿瘤学和放射肿瘤学的学术部门和部门沿着疾病导向的路线配置,以促进跨学科疾病导向和模式项目的增长和发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Munn Kirkwood其他文献

John Munn Kirkwood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Munn Kirkwood', 18)}}的其他基金

Melanoma and Skin Cancer Program SPORE
黑色素瘤和皮肤癌计划 SPORE
  • 批准号:
    10270227
  • 财政年份:
    2021
  • 资助金额:
    $ 22.77万
  • 项目类别:
Melanoma and Skin Cancer Program SPORE
黑色素瘤和皮肤癌计划 SPORE
  • 批准号:
    10469631
  • 财政年份:
    2021
  • 资助金额:
    $ 22.77万
  • 项目类别:
Melanoma and Skin Cancer Program SPORE
黑色素瘤和皮肤癌计划 SPORE
  • 批准号:
    10683750
  • 财政年份:
    2021
  • 资助金额:
    $ 22.77万
  • 项目类别:
Training Program in Skin Biology and Cancer
皮肤生物学和癌症培训计划
  • 批准号:
    9272850
  • 财政年份:
    2014
  • 资助金额:
    $ 22.77万
  • 项目类别:
Training Program in Skin Biology and Cancer
皮肤生物学和癌症培训计划
  • 批准号:
    8607635
  • 财政年份:
    2014
  • 资助金额:
    $ 22.77万
  • 项目类别:
Training Program in Skin Biology and Cancer
皮肤生物学和癌症培训计划
  • 批准号:
    8857377
  • 财政年份:
    2014
  • 资助金额:
    $ 22.77万
  • 项目类别:
Pilot Clinical & Molecular Analysis of Atypical Nevus Response to Sulforaphane
试点临床
  • 批准号:
    8302813
  • 财政年份:
    2012
  • 资助金额:
    $ 22.77万
  • 项目类别:
Pilot Clinical & Molecular Analysis of Atypical Nevus Response to Sulforaphane
试点临床
  • 批准号:
    8509629
  • 财政年份:
    2012
  • 资助金额:
    $ 22.77万
  • 项目类别:
SPORE in Skin Cancer
皮肤癌中的孢子
  • 批准号:
    8548580
  • 财政年份:
    2008
  • 资助金额:
    $ 22.77万
  • 项目类别:
Developmental Research Program
发展研究计划
  • 批准号:
    9091460
  • 财政年份:
    2008
  • 资助金额:
    $ 22.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了